NASDAQ : IFRX
InflaRx N.V. — Key statistics
Healthcare · Biotechnology · Germany
Last price 1.715 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 252.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 244.63M |
| Enterprise Value | 64.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 147.37M |
| Shares Outstanding | 147.37M |
| Shares Change (YoY) | +31.84% |
| Shares Change (QoQ) | +62.76% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 40.03% |
| Float | 98.11M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.46 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.22 |
| Quick Ratio | 7.95 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -582.09 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -38.52% |
| Return on Assets (ROA) | -18.54% |
| Return on Invested Capital (ROIC) | -21.78% |
| Return on Capital Employed (ROCE) | -24.29% |
| Weighted Average Cost of Capital (WACC) | 18.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$688,021 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 14,032 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.61 |
| 52-Week Price Change | +20.29% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 49.26 |
| Average Volume (20 Days) | 760,059 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.73M |
| Short Previous Month | 12.36M |
| Short % of Shares Out | 9.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 23.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | -11,540 |
| Gross Profit | -5.56M |
| Operating Income | -40.73M |
| Pretax Income | -44.71M |
| Net Income | -44.72M |
| EBITDA | -40.72M |
| EBIT | -40.73M |
| Loss Per Share | -$0.54 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 181.10M |
| Total Debt | 951,878 |
| Net Cash | 180.15M |
| Net Cash Per Share | $1.22 |
| Equity (Book Value) | 167.01M |
| Book Value Per Share | 1.13 |
| Working Capital | 165.97M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -26.48M |
| Capital Expenditures | -151,807 |
| Depreciation & Amortization | 13,031 |
| Net Borrowing | -345,300 |
| Free Cash Flow | -26.63M |
| FCF Per Share | -$0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | 352,966.34% |
| Pretax Margin | 387,411.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.84% |
| Shareholder Yield | -31.84% |
| Earnings Yield | -32.83% |
| FCF Yield | -10.89% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.29 |
| Price Target Difference | 399.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.14 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |